On October 10, 2019 Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, reported that the Company will present updates of clinical data from the MANIFEST clinical trial of CPI-0610 in oral and poster presentations at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting on December 9 (Press release, Constellation Pharmaceuticals, OCT 10, 2019, View Source [SID1234540945]). Two abstracts reflecting MANIFEST data have been accepted by ASH (Free ASH Whitepaper) and will be published on November 6. Updated data will be presented at the meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ASH Oral Presentation
Title: MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy or Add-On to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
Oral Session: 634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies
Date and Time: December 9, 11:15 AM
Location: Orange County Convention Center, W311EFGH, Orlando, FL
Dr. John Mascarenhas, Associate Professor of the Icahn School of Medicine at Mount Sinai and an investigator in the MANIFEST clinical trial, will give the oral presentation with interim data from MANIFEST.
ASH Poster Presentation
Title: Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III
Date and Time: Monday, December 9, 2019, Poster Display: 10:00 AM-8:00 PM EST, Poster Presentation: 6:00 PM-8:00 PM EST
Location: Orange County Convention Center, Hall B, Orlando, FL
Investor Event
Constellation will host an investor meeting and webcast conference call at 12:30 PM EST on December 9 at the Rosen Centre Hotel in Orlando to discuss the interim data from the MANIFEST oral presentation and poster at ASH (Free ASH Whitepaper). Further details will be provided later. If you would like to attend, please contact Ron Aldridge, Senior Director of Investor Relations, at [email protected].